期刊文献+

粪便生物标记物检测对溃疡性结肠炎的诊断价值研究 被引量:7

Diagnostic value of fecal biological markers in ulcerative colitis
下载PDF
导出
摘要 目的 研究两种粪便生物标记物乳铁蛋白、钙卫蛋白诊断溃疡性结肠炎(ulcerative colitis,UC)活动性的价值.方法 选择确诊的UC患者72例作为研究组,60例经结肠镜检查均正常的患者作为对照组,留取结肠镜检查3d内的粪便样本5~10g,应用ELISA方法进行粪便乳铁蛋白、钙卫蛋白检测.结果 粪便乳铁蛋白、钙卫蛋白水平在缓解组和对照组之间比较差异均无统计学意义(P>0.05);活动组分别与缓解组和对照组比较差异均有显著统计学意义(P<0.01);活动期各组之间相互比较差异均有统计学意义(P<0.01).粪便乳铁蛋白、钙卫蛋白水平与UC内镜分级标准呈正相关(r=0.873;0.891,P<0.01).结论 粪便乳铁蛋白、钙卫蛋白检测能够较准确地诊断UC活动期和缓解期,对临床治疗有指导作用. Objective To investigate the diagnostic value of lactoferrin and calprotectin in ulcerative colitis(UC).Methods Sixty patients as controls and 72 patients with UC as UC group were collected in this study.All patients were collected 5 ~ 10 g feces sample after colonoscopy during three days.An enzyme linked immunosorbent assay was used to determine fecal lactoferrin and calprotectin.Results The difference of fecal lactoferrin and calprotectin concentration between inactive UC group and control group was not statistically significant (P > 0.05) ; there was statistical significance of fecal lactoferrin and calprotectin concentration between active UC group and inactive UC group (P < 0.01) ; significant difference existed in active grades of UC each other (P < 0.01).The endoscopic grade of disease activity was related with fecal lactoferrin and calprotectin concentration (r =0.873 ;0.891,P < 0.01).Conclusion Patients with active or inactive UC were diagnosed by fecal lactoferrin and calprotectin detection.The directions of fecal lactoferrin and calprotectin to clinical medication of UC has gained better curative effect.
出处 《胃肠病学和肝病学杂志》 CAS 2014年第7期783-785,共3页 Chinese Journal of Gastroenterology and Hepatology
基金 河北省邯郸市科技局基金资助项目(NO1328108090-8)
关键词 乳铁蛋白 钙卫蛋白 ELISA方法 溃疡性结肠炎 Lactoferrin Calprotectin Enzyme linked immunosorbent assay Ulcerative colitis
  • 相关文献

参考文献14

  • 1Judd TA,Day AS,Lemberg DA,et al.Update of fecal markers of inflammation in inflammatory bowel disease[J].J Gastroenterol Hepatol,2011,26(10):1493-1499. 被引量:1
  • 2Abraham BP,Kane S.Fecal markers:calprotectin and lactoferrin[J].Gastroenterol Clin North Am,2012,41(2):483-495. 被引量:1
  • 3Stragier E,Van Assche G.The use of fecal calprotectin and lactoferrin in patients with IBD.Review[J].Acta Gastroenterol Belg,2013,76(3):322-328. 被引量:1
  • 4欧阳钦,潘国宗,温忠慧,万学红,胡仁伟,林三仁,胡品津.对炎症性肠病诊断治疗规范的建议[J].中华消化杂志,2001,21(4):236-239. 被引量:1124
  • 5D' Incà R,Dal Pont E,Di Leo V,et al.Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease[J].Int J Colorectal Dis,2007,22(4):429-437. 被引量:1
  • 6D'Haens G,Ferrante M,Vermeire S,et al.Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease[J].Inflamm Bowel Dis,2012,18(12):2218-2224. 被引量:1
  • 7Langhorst J,Boone J.Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases[J].Drugs Today(Barc),2012,48(2):149-161. 被引量:1
  • 8Sipponen T.Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin[J].Dig Dis,2013,31(3-4):336-344. 被引量:1
  • 9Costa F,Mumolo MG,Ceccarelli L,et al.Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn' s disease[J].Gut,2005,54(3):364-368. 被引量:1
  • 10Lamb CA,Mansfield JC.Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease[J].Frontline Gastroenterol,2011,2(1):13-18. 被引量:1

二级参考文献25

  • 1李世荣,王化虹,胡继春,李楠,刘玉兰,武子涛,郑悦,王洪华,吴凯,叶辉.三种粪隐血试验在结直肠癌筛检中的效率与费用分析[J].中华医学杂志,2005,85(10):697-700. 被引量:29
  • 2刘文斌,吕愈敏,金珠,杨雪玲.钙卫蛋白在溃疡性结肠炎患者结肠黏膜及粪便中的表达及临床意义[J].北京大学学报(医学版),2005,37(2):179-182. 被引量:17
  • 3Price AS. Primary and secondary prevention of colorectal cancer [ J]. Gastroenterol Nurs, 2003, 26 (2) : 73-75. 被引量:1
  • 4Strul H, Arber N. Fecal occult blood test for colorectal cancer screening [J]. Ann Oncol, 2002, 13(1): 51-53. 被引量:1
  • 5Mandel JS, Church Tit, Bond JH, et al. The effect of fecal occult blood screening on the incidence of colorectal cancer [ J ]. N Engl J Med, 2000, 343(10) : 1603-1607. 被引量:1
  • 6Lieherman DA, HarFord WV, Ahnen DJ, et al. One-time screening for eolorectal cancer with combined fecal occuh blood testing and examination of the distal colon [J]. N Engl J Med, 2001, 345(8) : 555-560. 被引量:1
  • 7Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis [ J ]. Nat Rev Cancer, 2005, 5 (3) : 199-209. 被引量:1
  • 8Syngal S, Stoffel E, Chung D, et al. Detection of stool DNA mutations be fore and after treatment of colorectal neoplasia [ J]. Cancer, 2006, 106(5) : 277-283. 被引量:1
  • 9Shimano T, Okuda H, Monden T, et al. Usefulness of carcino-embryonic antigen measurement in feces of patients with colorectal cancer [J]. Dis Colon Rectum, 1987, 30(3): 607-609. 被引量:1
  • 10Sturgeon C. Practice guidelines for turmor marker use in the clinic [J]. Clin Chem, 2002, 48(8): 1151-1159. 被引量:1

共引文献1125

同被引文献65

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部